Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials

Key Points

• The research evaluates the impact of nipocalimab on IgG antibody responses to vaccinations and viral infections.
• Conducted post hoc analyses of three randomized, placebo-controlled trials.
• Evaluated IgG responses in patients with IgG autoantibody-mediated diseases.
• Compared immunogenicity between nipocalimab and placebo groups.
• Nipocalimab treatment influenced IgG responses following vaccinations.
• Observed changes in responses to viral infections in the treatment group.
• Findings suggest potential benefits for enhancing immunogenicity in affected populations.